RPK Pharmaceuticals, Inc. dba Pharmedix – Trademark Portfolio
Entity Type: 03
RPK Pharmaceuticals, Inc. dba Pharmedix holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 2 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ONE WRITE and PHARMEDIX. The owner is based in Union City, CA.
3281 Whipple Road
Union City, CA 94587
Showing of trademarks Trademarks
Trademark Classifications
RPK Pharmaceuticals, Inc. dba Pharmedix's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does RPK Pharmaceuticals, Inc. dba Pharmedix have?
RPK Pharmaceuticals, Inc. dba Pharmedix has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does RPK Pharmaceuticals, Inc. dba Pharmedix file in?
RPK Pharmaceuticals, Inc. dba Pharmedix files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 16 (Paper Goods). Class 35 covers advertising; business management; business administration; office functions.
What are RPK Pharmaceuticals, Inc. dba Pharmedix's most well-known trademarks?
RPK Pharmaceuticals, Inc. dba Pharmedix's registered trademark portfolio includes well-known marks such as ONE WRITE and PHARMEDIX. These are among 2 currently registered trademarks in the portfolio.
What is RPK Pharmaceuticals, Inc. dba Pharmedix's trademark registration success rate?
RPK Pharmaceuticals, Inc. dba Pharmedix has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.